Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$11.82 +1.3%	$11.03	$7.34 ▼ $21.00	$538.28M	1.04	513,254 shs	620,922 shs
INFU InfuSystem	$5.50 +0.4%	$5.94	$4.61 ▼ $9.97	$115.59M	1.81	116,390 shs	90,050 shs
KIDS OrthoPediatrics	$22.56 +2.5%	$21.58	$19.52 ▼ $35.99	$547.92M	1.1	197,764 shs	128,973 shs
NPCE NeuroPace	$9.11 -2.6%	$12.53	$5.45 ▼ $18.98	$298.81M	1.93	186,439 shs	260,312 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	-2.91%	+1.66%	+19.69%	-25.10%	+34.76%
INFU InfuSystem	-2.32%	-10.60%	-11.76%	+10.04%	-19.77%
KIDS OrthoPediatrics	-0.63%	+1.48%	+3.97%	+6.85%	-33.09%
NPCE NeuroPace	-2.09%	-9.75%	-15.54%	-10.35%	+21.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXGN AxoGen	2.3016 of 5 stars	3.5	1.0	0.0	2.3	2.5	0.6
INFU InfuSystem	3.1102 of 5 stars	2.0	5.0	0.0	1.4	4.2	1.9
KIDS OrthoPediatrics	4.2664 of 5 stars	3.4	2.0	3.9	2.7	3.3	0.6
NPCE NeuroPace	3.543 of 5 stars	3.5	3.0	0.0	3.1	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	3.00	Buy	$24.50	107.28% Upside
INFU InfuSystem	4.00	Strong Buy	$13.00	136.36% Upside
KIDS OrthoPediatrics	2.86	Moderate Buy	$35.83	58.84% Upside
NPCE NeuroPace	3.00	Buy	$17.00	86.61% Upside

Current Analyst Ratings Breakdown

Latest INFU, KIDS, AXGN, and NPCE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	KIDS OrthoPediatrics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	NPCE NeuroPace	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
5/14/2025	NPCE NeuroPace	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $16.00
5/14/2025	NPCE NeuroPace	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$17.00 ➝ $17.00
5/13/2025	AXGN AxoGen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
5/8/2025	INFU InfuSystem	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	KIDS OrthoPediatrics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $30.00
5/8/2025	KIDS OrthoPediatrics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$187.34M	2.87	N/A	N/A	$2.36 per share	5.01
INFU InfuSystem	$137.58M	0.84	$0.43 per share	12.79	$2.47 per share	2.23
KIDS OrthoPediatrics	$212.45M	2.58	N/A	N/A	$14.64 per share	1.54
NPCE NeuroPace	$79.91M	3.74	N/A	N/A	$0.27 per share	33.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$9.96M	-$0.15	N/A	N/A	N/A	-3.68%	-7.09%	-3.67%	8/6/2025 (Estimated)
INFU InfuSystem	$870K	$0.14	91.68	17.74	N/A	1.12%	2.78%	1.41%	N/A
KIDS OrthoPediatrics	-$37.82M	-$1.75	N/A	N/A	N/A	-19.15%	-7.03%	-5.45%	8/4/2025 (Estimated)
NPCE NeuroPace	-$27.14M	-$0.84	N/A	N/A	N/A	-29.42%	-190.84%	-25.08%	8/12/2025 (Estimated)

Latest INFU, KIDS, AXGN, and NPCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	NPCE NeuroPace	-$0.24	N/A	N/A	N/A	$23.08 million	N/A
8/4/2025	Q2 2025	KIDS OrthoPediatrics	-$0.17	N/A	N/A	N/A	$61.40 million	N/A
5/13/2025	Q1 2025	NPCE NeuroPace	-$0.26	-$0.21	+$0.05	-$0.21	$21.85 million	$22.52 million
5/7/2025	Q1 2025	KIDS OrthoPediatrics	-$0.26	-$0.39	-$0.13	-$0.46	$51.68 million	$52.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A
KIDS OrthoPediatrics	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.63	4.28	2.65
INFU InfuSystem	0.50	1.98	1.59
KIDS OrthoPediatrics	0.21	6.19	2.99
NPCE NeuroPace	2.46	6.63	5.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
INFU InfuSystem	71.13%
KIDS OrthoPediatrics	69.05%
NPCE NeuroPace	78.83%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.78%
INFU InfuSystem	11.40%
KIDS OrthoPediatrics	31.80%
NPCE NeuroPace	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	45.54 million	44.28 million	Optionable
INFU InfuSystem	410	21.02 million	19.10 million	Optionable
KIDS OrthoPediatrics	200	24.29 million	16.56 million	Optionable
NPCE NeuroPace	170	32.80 million	26.08 million	Optionable

INFU, KIDS, AXGN, and NPCE Headlines

Recent News About These Companies

NeuroPace’s SWOT analysis: innovative epilepsy treatment stock faces growth hurdles - Investing.com

July 8, 2025 | investing.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. ...

July 6, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

July 2, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 27, 2025 | prnewswire.com

NeuroPace Announces Strategic CFO Transition - Morningstar

June 26, 2025 | morningstar.comM

NeuroPace, Inc.: NeuroPace Announces Strategic CFO Transition

June 25, 2025 | finanznachrichten.de

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE - Morningstar

June 24, 2025 | morningstar.comM

NeuroPace Announces Strategic CFO Transition

June 24, 2025 | globenewswire.com

NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm

June 24, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 23, 2025 | globenewswire.com

Palumbo Wealth Management LLC Has $567,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE)

June 23, 2025 | marketbeat.com

NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm

June 22, 2025 | gurufocus.com

NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm

June 22, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. ...

June 22, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 22, 2025 | prnewswire.com

NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of "Moderate Buy" by Brokerages

June 22, 2025 | marketbeat.com

NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey

June 17, 2025 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 16, 2025 | accessnewswire.comA

NeuroPace’s SWOT analysis: med tech stock poised for growth amid challenges

June 14, 2025 | investing.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 13, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect

June 13, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU, KIDS, AXGN, and NPCE Company Descriptions

AxoGen NASDAQ:AXGN

$11.82 +0.15 (+1.29%)

Closing price 04:00 PM Eastern

Extended Trading

$11.90 +0.08 (+0.67%)

As of 07:20 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

InfuSystem NYSE:INFU

$5.50 +0.02 (+0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$5.50 +0.00 (+0.09%)

As of 07:06 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

OrthoPediatrics NASDAQ:KIDS

$22.56 +0.56 (+2.55%)

Closing price 04:00 PM Eastern

Extended Trading

$22.58 +0.02 (+0.07%)

As of 04:10 PM Eastern

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

NeuroPace NASDAQ:NPCE

$9.11 -0.24 (-2.57%)

Closing price 04:00 PM Eastern

Extended Trading

$9.10 -0.01 (-0.16%)

As of 06:02 PM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time